Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
> 32 33 32 33 O
= 33 34 33 34 O
1.5 35 38 35 38 B-lower_bound
x 39 40 39 40 I-lower_bound
10 41 43 41 43 I-lower_bound
^ 43 44 43 44 I-lower_bound
9 44 45 44 45 I-lower_bound
/ 45 46 45 46 I-lower_bound
L 46 47 46 47 I-lower_bound

Active 0 6 48 54 B-chronic_disease
GVHD 7 11 55 59 I-chronic_disease
or 12 14 60 62 O
recent 15 21 63 69 O
GVHD 22 26 70 74 O
and 27 30 75 78 O
still 31 36 79 84 O
on 37 39 85 87 O
> 40 41 88 89 O
10 42 44 90 92 B-lower_bound
mg 45 47 93 95 I-lower_bound
prednisone 48 58 96 106 B-treatment
( 59 60 107 108 O
or 60 62 108 110 O
equivalent 63 73 111 121 O
) 73 74 121 122 O

Active 0 6 123 129 O
congestive 7 17 130 140 B-chronic_disease
heart 18 23 141 146 I-chronic_disease
failure 24 31 147 154 I-chronic_disease
( 32 33 155 156 O
New 33 36 156 159 O
York 37 41 160 164 O
Heart 42 47 165 170 O
Association 48 59 171 182 O
[ 60 61 183 184 O
NYHA 61 65 184 188 O
] 65 66 188 189 O
class 67 72 190 195 O
III 73 76 196 199 O
to 77 79 200 202 O
IV 80 82 203 205 O
) 82 83 205 206 O

Active 0 6 207 213 B-chronic_disease
life 7 11 214 218 I-chronic_disease
- 11 12 218 219 I-chronic_disease
threatening 12 23 219 230 I-chronic_disease
autoimmune 24 34 231 241 I-chronic_disease
disease 35 42 242 249 I-chronic_disease

Acute 0 5 250 255 B-chronic_disease
active 6 12 256 262 I-chronic_disease
infection 13 22 263 272 I-chronic_disease
requiring 23 32 273 282 O
intravenous 33 44 283 294 B-treatment
antibiotics 45 56 295 306 I-treatment

Age 0 3 307 310 B-age
> 4 5 311 312 O
/= 5 7 312 314 O
18 8 10 315 317 B-lower_bound
years 11 16 318 323 I-lower_bound
to 17 19 324 326 O
< 20 21 327 328 O
/= 21 23 328 330 O
80 24 26 331 333 B-upper_bound
years 27 32 334 339 I-upper_bound

Cardiac 0 7 340 347 B-clinical_variable
ejection 8 16 348 356 I-clinical_variable
fraction 17 25 357 365 I-clinical_variable
( 26 27 366 367 I-clinical_variable
EF 27 29 367 369 I-clinical_variable
) 29 30 369 370 I-clinical_variable
> 31 32 371 372 O
= 32 33 372 373 O
45 34 36 374 376 B-lower_bound
% 36 37 376 377 I-lower_bound
by 38 40 378 380 O
2 41 42 381 382 B-treatment
- 42 43 382 383 I-treatment
dimensional 43 54 383 394 I-treatment
echocardiogram 55 69 395 409 I-treatment
( 70 71 410 411 I-treatment
2D 71 73 411 413 I-treatment
- 73 74 413 414 I-treatment
ECHO 74 78 414 418 I-treatment
) 78 79 418 419 I-treatment
within 80 86 420 426 O
3 87 88 427 428 B-upper_bound
months 89 95 429 435 I-upper_bound
of 96 98 436 438 O
study 99 104 439 444 O
entry 105 110 445 450 O
( 111 112 451 452 O
or 112 114 452 454 O
within 115 121 455 461 O
1 122 123 462 463 B-upper_bound
month 124 129 464 469 I-upper_bound
if 130 132 470 472 O
received 133 141 473 481 O
chemotherapy 142 154 482 494 B-treatment
within 155 161 495 501 O
the 162 165 502 505 O
past 166 170 506 510 B-upper_bound
3 171 172 511 512 I-upper_bound
months 173 179 513 519 I-upper_bound
) 179 180 519 520 O

Deep 0 4 521 525 B-chronic_disease
vein 5 9 526 530 I-chronic_disease
thrombosis 10 20 531 541 I-chronic_disease
or 21 23 542 544 O
pulmonary 24 33 545 554 B-chronic_disease
embolism 34 42 555 563 I-chronic_disease
within 43 49 564 570 O
3 50 51 571 572 B-upper_bound
months 52 58 573 579 I-upper_bound
of 59 61 580 582 O
study 62 67 583 588 O
entry 68 73 589 594 O

Direct 0 6 595 601 B-clinical_variable
bilirubin 7 16 602 611 I-clinical_variable
< 17 18 612 613 O
1.6 19 22 614 617 B-upper_bound
( 23 24 618 619 O
unless 24 30 619 625 O
related 31 38 626 633 O
to 39 41 634 636 O
Gilbert 42 49 637 644 B-chronic_disease
's 49 51 644 646 I-chronic_disease
disease 52 59 647 654 I-chronic_disease
or 60 62 655 657 O
medications 63 74 658 669 O
) 74 75 669 670 O

Females 0 7 671 678 B-gender
of 8 10 679 681 O
childbearing 11 23 682 694 O
potential 24 33 695 704 O
( 34 35 705 706 O
FCBP 35 39 706 710 O
) 39 40 710 711 O
must 41 45 712 716 O
have 46 50 717 721 O
a 51 52 722 723 O
negative 53 61 724 732 B-pregnancy
serum 62 67 733 738 I-pregnancy
or 68 70 739 741 I-pregnancy
urine 71 76 742 747 I-pregnancy
pregnancy 77 86 748 757 I-pregnancy
test 87 91 758 762 O
with 92 96 763 767 O
a 97 98 768 769 O
sensitivity 99 110 770 781 O
of 111 113 782 784 O
at 114 116 785 787 O
least 117 122 788 793 O
50 123 125 794 796 B-lower_bound
mIU 126 129 797 800 I-lower_bound
/ 129 130 800 801 I-lower_bound
mL 130 132 801 803 I-lower_bound
within 133 139 804 810 O
10 140 142 811 813 B-lower_bound
- 142 143 813 814 O
14 143 145 814 816 B-upper_bound
days 146 150 817 821 I-upper_bound
prior 151 156 822 827 I-upper_bound
to 157 159 828 830 O
study 160 165 831 836 O
entry 166 171 837 842 O

Forced 0 6 843 849 B-clinical_variable
expiratory 7 17 850 860 I-clinical_variable
volume 18 24 861 867 I-clinical_variable
in 25 27 868 870 I-clinical_variable
one 28 31 871 874 I-clinical_variable
second 32 38 875 881 I-clinical_variable
( 39 40 882 883 I-clinical_variable
FEV1 40 44 883 887 I-clinical_variable
) 44 45 887 888 I-clinical_variable

Hematologic 0 11 889 900 B-cancer
or 12 14 901 903 I-cancer
lymphoid 15 23 904 912 I-cancer
malignancy 24 34 913 923 I-cancer

Immunotherapy 0 13 924 937 B-treatment
or 14 16 938 940 O
chemotherapy 17 29 941 953 B-treatment
with 30 34 954 958 O
approved 35 43 959 967 O
or 44 46 968 970 O
investigational 47 62 971 986 O
anticancer 63 73 987 997 O
therapeutics 74 86 998 1010 O
within 87 93 1011 1017 O
4 94 95 1018 1019 B-upper_bound
weeks 96 101 1020 1025 I-upper_bound
of 102 104 1026 1028 O
first 105 110 1029 1034 O
dose 111 115 1035 1039 O

Known 0 5 1040 1045 O
human 6 11 1046 1051 B-chronic_disease
immunodeficiency 12 28 1052 1068 I-chronic_disease
virus 29 34 1069 1074 I-chronic_disease
( 35 36 1075 1076 I-chronic_disease
HIV 36 39 1076 1079 I-chronic_disease
) 39 40 1079 1080 I-chronic_disease
seropositive 41 53 1081 1093 O

Known 0 5 1094 1099 O
hypersensitivity 6 22 1100 1116 O
to 23 25 1117 1119 O
thalidomide 26 37 1120 1131 B-allergy_name
, 37 38 1131 1132 O
lenalidomide 39 51 1133 1145 B-allergy_name
or 52 54 1146 1148 O
ipilimumab 55 65 1149 1159 B-allergy_name

No 0 2 1160 1162 O
active 3 9 1163 1169 B-chronic_disease
infection 10 19 1170 1179 I-chronic_disease

Patients 0 8 1180 1188 O
on 9 11 1189 1191 O
alemtuzumab 12 23 1192 1203 B-treatment
within 24 30 1204 1210 O
6 31 32 1211 1212 B-upper_bound
weeks 33 38 1213 1218 I-upper_bound
prior 39 44 1219 1224 I-upper_bound
to 45 47 1225 1227 O
consenting 48 58 1228 1238 O

Patients 0 8 1239 1247 O
with 9 13 1248 1252 O
other 14 19 1253 1258 O
known 20 25 1259 1264 O
malignancies 26 38 1265 1277 B-cancer
within 39 45 1278 1284 O
the 46 49 1285 1288 O
past 50 54 1289 1293 B-upper_bound
three 55 60 1294 1299 I-upper_bound
years 61 66 1300 1305 I-upper_bound

Performance 0 11 1306 1317 O
status 12 18 1318 1324 O
: 18 19 1324 1325 O
Eastern 20 27 1326 1333 B-clinical_variable
Cooperative 28 39 1334 1345 I-clinical_variable
Oncology 40 48 1346 1354 I-clinical_variable
Group 49 54 1355 1360 I-clinical_variable
( 55 56 1361 1362 I-clinical_variable
ECOG 56 60 1362 1366 I-clinical_variable
) 60 61 1366 1367 I-clinical_variable
2 62 63 1368 1369 B-upper_bound
or 64 66 1370 1372 O
less 67 71 1373 1377 O
or 72 74 1378 1380 O
Karnofsky 75 84 1381 1390 B-clinical_variable
of 85 87 1391 1393 O
at 88 90 1394 1396 O
least 91 96 1397 1402 O
60 97 99 1403 1405 B-lower_bound

Platelets 0 9 1406 1415 B-clinical_variable
> 10 11 1416 1417 O
75 12 14 1418 1420 B-lower_bound
x 15 16 1421 1422 I-lower_bound
10 17 19 1423 1425 I-lower_bound
^ 19 20 1425 1426 I-lower_bound
9 20 21 1426 1427 I-lower_bound
/ 21 22 1427 1428 I-lower_bound
L 22 23 1428 1429 I-lower_bound

Pregnant 0 8 1430 1438 B-pregnancy

Prior 0 5 1439 1444 O
auto 6 10 1445 1449 B-chronic_disease
- 10 11 1449 1450 I-chronic_disease
immune 11 17 1450 1456 I-chronic_disease
disease 18 25 1457 1464 I-chronic_disease

Serum 0 5 1465 1470 B-clinical_variable
creatinine 6 16 1471 1481 I-clinical_variable
= 17 18 1482 1483 O
< 18 19 1483 1484 O
1.6 20 23 1485 1488 B-upper_bound
mg 24 26 1489 1491 I-upper_bound
/ 26 27 1491 1492 I-upper_bound
dL 27 29 1492 1494 I-upper_bound
and 30 33 1495 1498 O
creatinine 34 44 1499 1509 B-clinical_variable
clearance 45 54 1510 1519 I-clinical_variable
> 55 56 1520 1521 O
= 56 57 1521 1522 O
30 58 60 1523 1525 B-lower_bound
ml 61 63 1526 1528 I-lower_bound
/ 63 64 1528 1529 I-lower_bound
min 64 67 1529 1532 I-lower_bound

Serum 0 5 1533 1538 B-clinical_variable
glutamate 6 15 1539 1548 I-clinical_variable
pyruvate 16 24 1549 1557 I-clinical_variable
transaminase 25 37 1558 1570 I-clinical_variable
( 38 39 1571 1572 I-clinical_variable
SGPT 39 43 1572 1576 I-clinical_variable
) 43 44 1576 1577 I-clinical_variable
, 44 45 1577 1578 O
serum 46 51 1579 1584 B-clinical_variable
glutamic 52 60 1585 1593 I-clinical_variable
oxaloacetic 61 72 1594 1605 I-clinical_variable
transaminase 73 85 1606 1618 I-clinical_variable
( 86 87 1619 1620 I-clinical_variable
SGOT 87 91 1620 1624 I-clinical_variable
) 91 92 1624 1625 I-clinical_variable
less 93 97 1626 1630 O
than 98 102 1631 1635 O
2 103 104 1636 1637 B-upper_bound
x 105 106 1638 1639 I-upper_bound
the 107 110 1640 1643 I-upper_bound
upper 111 116 1644 1649 I-upper_bound
limit 117 122 1650 1655 I-upper_bound
of 123 125 1656 1658 I-upper_bound
normal 126 132 1659 1665 I-upper_bound
range 133 138 1666 1671 I-upper_bound
( 139 140 1672 1673 O
unless 140 146 1673 1679 O
related 147 154 1680 1687 O
to 155 157 1688 1690 O
Gilbert 158 165 1691 1698 B-chronic_disease
's 165 167 1698 1700 I-chronic_disease
disease 168 175 1701 1708 I-chronic_disease
or 176 178 1709 1711 O
medications 179 190 1712 1723 O
) 190 191 1723 1724 O

Significant 0 11 1725 1736 O
neuropathy 12 22 1737 1747 B-chronic_disease
( 23 24 1748 1749 O
grades 24 30 1749 1755 B-lower_bound
3 31 32 1756 1757 I-lower_bound
to 33 35 1758 1760 O
4 36 37 1761 1762 B-upper_bound
or 38 40 1763 1765 O
grade 41 46 1766 1771 O
2 47 48 1772 1773 O
pain 49 53 1774 1778 O
) 53 54 1778 1779 O

adequately 0 10 1780 1790 O
treated 11 18 1791 1798 O
basal 19 24 1799 1804 B-cancer
or 25 27 1805 1807 I-cancer
squamous 28 36 1808 1816 I-cancer
cell 37 41 1817 1821 I-cancer
skin 42 46 1822 1826 I-cancer
cancer 47 53 1827 1833 I-cancer

antifungal 0 10 1834 1844 B-treatment
agents 11 17 1845 1851 I-treatment
within 18 24 1852 1858 O
14 25 27 1859 1861 B-upper_bound
days 28 32 1862 1866 I-upper_bound
of 33 35 1867 1869 O
first 36 41 1870 1875 O
dose 42 46 1876 1880 O

antiviral 0 9 1881 1890 O
( 10 11 1891 1892 O
except 11 17 1892 1898 O
antiviral 18 27 1899 1908 O
directed 28 36 1909 1917 O
at 37 39 1918 1920 O
hepatitis 40 49 1921 1930 B-chronic_disease
B 50 51 1931 1932 I-chronic_disease
) 51 52 1932 1933 O

breast 0 6 1934 1940 B-cancer
cancer 7 13 1941 1947 I-cancer
in 14 16 1948 1950 I-cancer
situ 17 21 1951 1955 I-cancer
with 22 26 1956 1960 O
full 27 31 1961 1965 B-treatment
surgical 32 40 1966 1974 I-treatment
resection 41 50 1975 1984 I-treatment

breast 0 6 1985 1991 O
- 6 7 1991 1992 O
feeding 7 14 1992 1999 O
females 15 22 2000 2007 B-gender

carcinoma 0 9 2008 2017 B-cancer
in 10 12 2018 2020 I-cancer
situ 13 17 2021 2025 I-cancer
of 18 20 2026 2028 I-cancer
the 21 24 2029 2032 I-cancer
cervix 25 31 2033 2039 I-cancer

creatinine 0 10 2040 2050 B-clinical_variable
clearance 11 20 2051 2060 I-clinical_variable
will 21 25 2061 2065 O
be 26 28 2066 2068 O
calculated 29 39 2069 2079 O
using 40 45 2080 2085 O
the 46 49 2086 2089 O
Cockcroft 50 59 2090 2099 B-clinical_variable
- 59 60 2099 2100 I-clinical_variable
Gault 60 65 2100 2105 I-clinical_variable
equation 66 74 2106 2114 I-clinical_variable

diffusing 0 9 2115 2124 B-clinical_variable
capacity 10 18 2125 2133 I-clinical_variable
of 19 21 2134 2136 I-clinical_variable
the 22 25 2137 2140 I-clinical_variable
lung 26 30 2141 2145 I-clinical_variable
for 31 34 2146 2149 I-clinical_variable
carbon 35 41 2150 2156 I-clinical_variable
monoxide 42 50 2157 2165 I-clinical_variable
( 51 52 2166 2167 I-clinical_variable
DLCO 52 56 2167 2171 I-clinical_variable
) 56 57 2171 2172 I-clinical_variable
> 58 59 2173 2174 O
= 59 60 2174 2175 O
40 61 63 2176 2178 B-lower_bound
% 63 64 2178 2179 I-lower_bound
within 65 71 2180 2186 O
3 72 73 2187 2188 B-upper_bound
months 74 80 2189 2195 I-upper_bound
of 81 83 2196 2198 O
study 84 89 2199 2204 O
entry 90 95 2205 2210 O
( 96 97 2211 2212 O
or 97 99 2212 2214 O
within 100 106 2215 2221 O
1 107 108 2222 2223 B-upper_bound
month 109 114 2224 2229 I-upper_bound
if 115 117 2230 2232 O
received 118 126 2233 2241 O
chemotherapy 127 139 2242 2254 B-treatment
within 140 146 2255 2261 O
the 147 150 2262 2265 O
past 151 155 2266 2270 B-upper_bound
3 156 157 2271 2272 I-upper_bound
months 158 164 2273 2279 I-upper_bound
) 164 165 2279 2280 O

forced 0 6 2281 2287 B-clinical_variable
vital 7 12 2288 2293 I-clinical_variable
capacity 13 21 2294 2302 I-clinical_variable
( 22 23 2303 2304 I-clinical_variable
FVC 23 26 2304 2307 I-clinical_variable
) 26 27 2307 2308 I-clinical_variable

hepatitis 0 9 2309 2318 B-chronic_disease
B 10 11 2319 2320 I-chronic_disease

hepatitis 0 9 2321 2330 B-chronic_disease
C 10 11 2331 2332 I-chronic_disease
infection 12 21 2333 2342 O

lactating 0 9 2343 2352 O
females 10 17 2353 2360 B-gender
must 18 22 2361 2365 O
agree 23 28 2366 2371 O
not 29 32 2372 2375 O
to 33 35 2376 2378 O
breast 36 42 2379 2385 O
- 42 43 2385 2386 O
feed 43 47 2386 2390 O
while 48 53 2391 2396 O
taking 54 60 2397 2403 O
lenalidomide 61 73 2404 2416 B-treatment

myocardial 0 10 2417 2427 B-chronic_disease
infarction 11 21 2428 2438 I-chronic_disease
within 22 28 2439 2445 O
6 29 30 2446 2447 B-upper_bound
months 31 37 2448 2454 I-upper_bound
of 38 40 2455 2457 O
study 41 46 2458 2463 O
entry 47 52 2464 2469 O

patients 0 8 2470 2478 O
with 9 13 2479 2483 O
hepatitis 14 23 2484 2493 B-chronic_disease
B 24 25 2494 2495 I-chronic_disease
surface 26 33 2496 2503 I-chronic_disease
antigen 34 41 2504 2511 I-chronic_disease
[ 42 43 2512 2513 O
Sag 43 46 2513 2516 O
] 46 47 2516 2517 O
or 48 50 2518 2520 O
core 51 55 2521 2525 O
antibody 56 64 2526 2534 O
receiving 65 74 2535 2544 O
and 75 78 2545 2548 O
responding 79 89 2549 2559 O
to 90 92 2560 2562 O
antiviral 93 102 2563 2572 B-treatment
therapy 103 110 2573 2580 I-treatment
directed 111 119 2581 2589 O
at 120 122 2590 2592 O
hepatitis 123 132 2593 2602 O
B 133 134 2603 2604 O

prostate 0 8 2605 2613 B-cancer
cancer 9 15 2614 2620 I-cancer
with 16 20 2621 2625 O
Gleason 21 28 2626 2633 B-clinical_variable
score 29 34 2634 2639 I-clinical_variable
< 35 36 2640 2641 O
6 37 38 2642 2643 B-upper_bound
with 39 43 2644 2648 O
stable 44 50 2649 2655 O
prostate 51 59 2656 2664 B-clinical_variable
- 59 60 2664 2665 I-clinical_variable
specific 60 68 2665 2673 I-clinical_variable
antigen 69 76 2674 2681 I-clinical_variable
( 77 78 2682 2683 I-clinical_variable
PSA 78 81 2683 2686 I-clinical_variable
) 81 82 2686 2687 I-clinical_variable
over 83 87 2688 2692 O
the 88 91 2693 2696 O
past 92 96 2697 2701 B-upper_bound
three 97 102 2702 2707 I-upper_bound
months 103 109 2708 2714 I-upper_bound

symptomatic 0 11 2715 2726 B-chronic_disease
ischemia 12 20 2727 2735 I-chronic_disease
or 21 23 2736 2738 O
conduction 24 34 2739 2749 O
abnormalities 35 48 2750 2763 O
uncontrolled 49 61 2764 2776 O
by 62 64 2777 2779 O
conventional 65 77 2780 2792 O
interventions 78 91 2793 2806 O

